Recognition of this kind is worth more than it first appears, because of how modern drug regulation actually works. Regulators across the developing world lack the laboratories and specialist staff to independently assess every medicine, and the response has been reliance - accepting the assessment of a trusted authority rather than duplicating it. That only functions if some authority is trusted, and designating IPC a Regional Centre of Excellence in Pharmacovigilance and a Technical Centre in Quality of Medicines is precisely such a designation for the South-East Asia Region. The practical effect is that other Member States can lean on Indian standards and Indian safety data instead of building their own from scratch. There is also a commercial dimension India cannot ignore. India supplies a very large share of global generic medicines, and its export position is periodically damaged by quality incidents that make headlines abroad. Institutional recognition of the body that writes India's drug standards is a partial answer to that reputational exposure - though it is worth being clear that recognising the standard-setter is not the same as guaranteeing every manufacturer complies, which remains the work of the drug controllers and inspectors rather than of the pharmacopoeia commission. Note too where WHO SEARO itself is headquartered - New Delhi - which is a small fact examiners like.